Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453085 | 0.91 | CYP2D6 (0.62) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL13453082 | 0.84 | KDM4E (0.50) | TSHRSIGMAR1MCHR1KDM4E | |
| SCHEMBL3243860 | 0.77 | TSHR (0.76) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL3243863 | 0.77 | TSHR (0.76) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL12852778 | 0.76 | KDM4E (0.46) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL1205432 | 0.76 | CHRM4 (0.52) | CYP2D6CYP2C9SIGMAR1DPP7DRD4 | |
| SCHEMBL3960093 | 0.76 | SIGMAR1 (0.56) | CYP2D6CYP2C9CYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL14264751 | 0.76 | CYP2C19 (0.64) | TSHRCYP2D6CYP2C9CYP2C19SIGMAR1 | |
| SCHEMBL23201807 | 0.74 | GAA (0.61) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10481422 | 0.74 | GAA (0.61) | TSHRCYP2D6CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233950-B2 | Co-crystals and salts of CCR3-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20150105371-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8742115-B2 | Co-crystals and salts of CCR3-inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20140135307-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264729-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | TSHR 2075/4885CYP2D6 2085/4885CYP2C9 1025/4885 |
| US-20140135307-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | TSHR 2075/4885CYP2D6 2085/4885CYP2C9 1025/4885 |
| US-20150105371-A1 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS | CCR3, CCR1, CCR4 | TSHR 2075/4885CYP2D6 2085/4885CYP2C9 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.